Apogee Therapeutics, Inc.
APGE
$41.86
-$0.58-1.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.71M | 15.65M | 12.97M | 10.92M | 9.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.10M | 75.88M | 58.69M | 44.12M | 38.18M |
| Operating Income | -63.10M | -75.88M | -58.69M | -44.12M | -38.18M |
| Income Before Tax | -55.26M | -67.20M | -49.02M | -33.82M | -32.09M |
| Income Tax Expenses | 83.00K | 18.00K | -- | -- | -- |
| Earnings from Continuing Operations | -55.34M | -67.22M | -49.02M | -33.82M | -32.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.34M | -67.22M | -49.02M | -33.82M | -32.09M |
| EBIT | -63.10M | -75.88M | -58.69M | -44.12M | -38.18M |
| EBITDA | -62.89M | -75.81M | -58.64M | -44.09M | -38.15M |
| EPS Basic | -0.95 | -1.17 | -0.86 | -0.60 | -0.64 |
| Normalized Basic EPS | -0.59 | -0.73 | -0.54 | -0.37 | -0.40 |
| EPS Diluted | -0.95 | -1.17 | -0.86 | -0.60 | -0.64 |
| Normalized Diluted EPS | -0.59 | -0.73 | -0.54 | -0.37 | -0.40 |
| Average Basic Shares Outstanding | 58.20M | 57.25M | 56.80M | 56.52M | 50.19M |
| Average Diluted Shares Outstanding | 58.20M | 57.25M | 56.80M | 56.52M | 50.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |